Lanreotide-Induced Modulation of 5-Fluorouracil or Mitomycin C Cytotoxicity in Human Colon Cancer Cell Lines: a Preclinical Study

REFERENCES

• Sobrero AF. Mechanism of drug action in colorectal cancer treatment. In: Bleiberg H, Rougier P, and Wilke HJ eds. Management of colorectal cancer. London: Martin Dunitz Ltd, 1998: 199–210 .
   Google Scholar
• Petrelli NJ, Mittelman A. An analysis of chemotherapy for colorectal carcinoma. J Surg Oncol 1984; 25: 201–6.
   PubMed Web of Science ®Google Scholar
• Slevin ML, Papamichael D, Rougier P, Schmoll HJ. Current controversies in Cancer. Is there a standard adjuvant treatment for colon cancer? Eur J Cancer 1998; 34: 1652–63.
   PubMed Web of Science ®Google Scholar
• Patel YC, Zing HH, Fitz-Patrick D, Srikant CB. Somatostatin: some aspects of its physiology and pathophysi-ology. In: Bloom SR, and Pollack JM eds. Gut Hormones. Edinburgh: Churchill Livingstone, 1981: 339–49.
   Google Scholar
• Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991; 50: 245–51.
   PubMed Web of Science ®Google Scholar
• Partsch G, Matucci-Cerinic M. Effect of substance P and somatostatin on migration of polymorphonuclear (PMN) cells in vitro. Inflammation 1992; 16: 539–47.
   PubMed Web of Science ®Google Scholar
• Buscail L, Delesque N, Esteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994; 91: 2315–9.
   PubMed Web of Science ®Google Scholar
• Buscail L, Esteve JP, Saint Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995; 92: 1580-84.
   Google Scholar
• Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20: 348–67.
   PubMed Web of Science ®Google Scholar
• Viollet C, Prevost G, Maubert E, et al. Molecular phar-macology of somatostatin receptors. Fundam Clin Pharmacol 1995; 9: 107–13.
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427–42.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994, 54: 3455–9.
   PubMed Web of Science ®Google Scholar
• Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sstl, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with recep-tor autoradiography. Int J Cancer 1997; 70: 530–7.
   PubMed Web of Science ®Google Scholar
• Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR-5) in pituitary tumors. Life Sci 1995; 56: 333–42.
   PubMed Web of Science ®Google Scholar
• Tisell LE, Ahlman H, Wanberg B, et al. Expression of somatostatin receptors in oncocytic (Hurthle cell) neoplasia of the thyroid. Br J Cancer 1999; 79: 1579–82.
   PubMed Web of Science ®Google Scholar
• Schally AV, Coy DH, Meyers CA. Hypothalamic regu-latory hormones. Annu Rev Biochem 1978; 47: 89–128.
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450–82.
   PubMed Web of Science ®Google Scholar
• Qin Y, Schally AV, Willems G. Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats. Int J Cancer 1991, 47: 765–70.
   PubMed Web of Science ®Google Scholar
• Dy DY, Whitehead RH, Morris DL. SMS 201-995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 1992, 52: 917–23.
   PubMed Web of Science ®Google Scholar
• Romani R, Morris DL. SMS 201-995 (Sandostatin) enhances in vitro effects of 5-fluorouracil in colorectal cancer. Eur J Surg Oncol 1995, 21: 27–32.
   PubMedGoogle Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colon-metric cytotoxic assay for anticancer drug screening. J Natl Cancer Inst 1990; 13: 1107–12.
   Google Scholar
• Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittclforsch 1953; 3: 285–320.
   PubMed Web of Science ®Google Scholar
• Berenbaum MC. Interaction of biologically active agents. Adv Cancer Res 1981; 35: 269–335.
   PubMed Web of Science ®Google Scholar
• Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivi-ty. Int J Rad Oncol 1979; 5: 85–91.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1987; 22: 27–55.
   Google Scholar
• Kanzawa F, Nishio K, Fukuoka K, Sunami T, Saijo N. In vitro interactions of a new derivative of spycamycin, KRNS500, and other anticancer drugs using a three-dimen-sional model. Cancer Chemother Pharmacol 1999; 43: 353–63.
   PubMed Web of Science ®Google Scholar
• Webb JL. Effect of more than one inhibitor, antago-nism, summation, and synergism. In: Enzyme and Metabolic Inhibitors; New York Academic Press, 1963, vol 1: 488–512.
   Google Scholar
• Sestini R, Orlando C, Zentilin L, et al. Measurement of gene amplification for c-erbB-2, c-myc, epidermal growth fac-tor receptor, int-2 and N-myc by quantitative PCR with a mul-tiple competitor template. Clin Chem 1995; 41: 826–32.
   PubMed Web of Science ®Google Scholar
• Sestini R, Orlando C, Pen i A, et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblas-toma cell line and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 1996, 2: 1757–65.
   Google Scholar
• Orlando C, Sestini R, Zentilin L, et al. Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 amplification in DNA from human tumors. J Biolum Chemilum 1994; 9: 223–8.
   Google Scholar
• Smith JP, Solomon TE. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology 1988; 95: 1541–8.
   PubMed Web of Science ®Google Scholar
• Townsend CM Jr, Singh P, Thompson JC. Effects of gastrointestinal peptides on gastrointestinal cancer growth. Gastroenterol Clin North Am 1989; 18: 777–91.
   PubMed Web of Science ®Google Scholar
• Lahm H, Suardet L, Laurent PL, et al. Growth regula-tion and co-stimulation of human colorectal cancer cell lines by insulin-like growth factors I, II and transforming growth fac-tor alpha. Br J Cancer 1992; 65: 341–6.
   PubMed Web of Science ®Google Scholar
• Stewart GJ, Connor JL, Lawson JA, Preketes A, King J, Morris DL. Octreotide reduces the kinetic index, proliferat-ing cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer. Cancer 1995; 76: 572–8.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Bajetta E, Ferrari L, et al. A dose-finding study of lanreotide (a somatostatin analog) in patients with col-orectal carcinoma. Cancer 1996; 78: 35–42.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Del Ferro E, Grianti C, et al. Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology 1997; 113: 767–72.
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Dobbs N, Propper DJ, et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999; 79: 1413–8.
   PubMed Web of Science ®Google Scholar
• Klijn JG, Hoff AM, Planting AS, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phaseII study including endocrine effects. Br J Cancer 1990; 62: 627–30.
   PubMed Web of Science ®Google Scholar
• Smith JP, Doll D, Croitoru R, Thornton C, Perry MC. Octreotide has no effect on advanced colon cancer. J Clin Gastroenterol 1994; 18: 245–7.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Moertel CG, Wieand HS, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carci-noma. North Central Cancer Treatment Group and the Mayo Clinic. Cancer 1995; 76: 961–6.
   Google Scholar
• Cascinu S, Del Ferro E, Catalano GA. Randomised trial of octreotide vs best supportive care only in advanced gas-trointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995; 71: 97–101.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Wieand HS, Krook JE, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treat-ment of patients with asymptomatic advanced colon carcino-ma. Author reply. Cancer 1996; 77: 1956–7.
   Google Scholar
• Weckbecker G, RauIf F, Tolcsvai L, Bruns C. Potentation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 1996; 57: 22–8 .
   PubMed Web of Science ®Google Scholar
• Laws S, Gough AC, Evans AA, Bains MA, Primrose JN. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer 1997; 75: 360–6.
   PubMed Web of Science ®Google Scholar
• Pagliacci MC, Tognellini R, Grignani F Nicoletti I. Inhibition of human breast cancer cell (MCF-7). Growth in vitro by the somatostatin analog SMS 201-995: effect on cell cycle parameters and apoptotic cell death. Endocrinology 1991; 129: 2555–61.
   Google Scholar
• Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumour cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995; 136: 4174-80.
   Google Scholar
• Sharma K, Srikant CB. Induction of wild type p53, bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998; 76: 259–66.
   PubMed Web of Science ®Google Scholar
• Presky DH, Schobrunn A. Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 1988; 263: 714–21.
   PubMed Web of Science ®Google Scholar
• Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996; 137: 4046–9.
   PubMed Web of Science ®Google Scholar